Regeneron Pharmaceuticals (NASDAQ:REGN) PT Set at $344.00 by BMO Capital Markets

BMO Capital Markets set a $344.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report sent to investors on Tuesday, TipRanks reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on REGN. Cowen restated a hold rating and set a $353.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, July 29th. Guggenheim upgraded shares of Regeneron Pharmaceuticals from a neutral rating to a buy rating and upped their price objective for the stock from $355.00 to $403.00 in a report on Monday, September 23rd. Robert W. Baird upgraded shares of Regeneron Pharmaceuticals from a neutral rating to an outperform rating and set a $410.00 price objective on the stock in a report on Wednesday, August 7th. Canaccord Genuity lowered their price objective on shares of Regeneron Pharmaceuticals from $353.00 to $320.00 and set a hold rating on the stock in a report on Wednesday. Finally, JPMorgan Chase & Co. restated a hold rating on shares of Regeneron Pharmaceuticals in a report on Friday, June 21st. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $394.56.

Regeneron Pharmaceuticals stock opened at $300.77 on Tuesday. The company has a quick ratio of 3.11, a current ratio of 3.88 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average is $286.11 and its 200 day moving average is $315.65. Regeneron Pharmaceuticals has a 12-month low of $271.37 and a 12-month high of $442.00. The company has a market capitalization of $31.31 billion, a PE ratio of 15.19, a PEG ratio of 1.30 and a beta of 1.14.



Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.60 by $0.69. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The firm had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the company posted $5.45 earnings per share. The business’s revenue was up 20.3% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals will post 19.22 EPS for the current fiscal year.

In other news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total value of $48,611,959.60. Corporate insiders own 11.84% of the company’s stock.

Several hedge funds have recently made changes to their positions in REGN. Point72 Asset Management L.P. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $151,443,000. Parnassus Investments CA grew its position in Regeneron Pharmaceuticals by 290.6% during the second quarter. Parnassus Investments CA now owns 625,000 shares of the biopharmaceutical company’s stock valued at $195,625,000 after buying an additional 465,000 shares during the period. Nuveen Asset Management LLC grew its position in Regeneron Pharmaceuticals by 700.5% during the second quarter. Nuveen Asset Management LLC now owns 352,815 shares of the biopharmaceutical company’s stock valued at $110,432,000 after buying an additional 308,740 shares during the period. Prudential Financial Inc. grew its position in Regeneron Pharmaceuticals by 190.2% during the second quarter. Prudential Financial Inc. now owns 227,517 shares of the biopharmaceutical company’s stock valued at $71,213,000 after buying an additional 149,111 shares during the period. Finally, Renaissance Technologies LLC grew its position in Regeneron Pharmaceuticals by 62.3% during the second quarter. Renaissance Technologies LLC now owns 337,962 shares of the biopharmaceutical company’s stock valued at $105,782,000 after buying an additional 129,700 shares during the period. Institutional investors own 66.54% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: Mutual Funds

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.